Annual Financials for Annovis Bio Inc.
Operating Activities
Fiscal year is January-December. All values USD millions. |
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
Net Income before Extraordinaries |
(682,349) | (713,871) | (990,980) | (5.46M) | (14.49M) | |
Net Income Growth |
- | -4.62% | -38.82% | -451.18% | -165.23% | |
Depreciation, Depletion & Amortization |
- | - | - | - | - | |
Depreciation and Depletion |
- | - | - | - | - | |
Amortization of Intangible Assets |
- | - | - | - | - | |
Deferred Taxes & Investment Tax Credit |
- | - | - | - | - | |
Deferred Taxes |
- | - | - | - | - | |
Investment Tax Credit |
- | - | - | - | - | |
Other Funds |
48,495 | 82,728 | 92,912 | 1.89M | 4.7M | |
Funds from Operations |
(633,854) | (631,143) | (898,068) | (3.57M) | (9.79M) | |
Extraordinaries |
- | - | - | - | - | |
Changes in Working Capital |
96,373 | 72,534 | 421,526 | (400,714) | 657,346 | |
Receivables |
- | - | (735,075) | 735,075 | - | |
Accounts Payable |
36,914 | (2,682) | 969,091 | (695,660) | 346,218 | |
Other Assets/Liabilities |
(2,368) | (5,189) | 5,101 | (34,097) | (270,788) | |
Net Operating Cash Flow |
(537,481) | (558,609) | (476,542) | (3.97M) | (9.13M) | |
Net Operating Cash Flow Growth |
- | -3.93% | 14.69% | -733.26% | -129.98% | |
Net Operating Cash Flow / Sales |
- | - | - | - | - | |
Investing Activities
|
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
Capital Expenditures |
- | - | - | - | - | |
Capital Expenditures (Fixed Assets) |
- | - | - | - | - | |
Capital Expenditures (Other Assets) |
- | - | - | - | - | |
Capital Expenditures Growth |
- | - | - | - | - | |
Capital Expenditures / Sales |
- | - | - | - | - | |
Net Assets from Acquisitions |
- | - | - | - | - | |
Sale of Fixed Assets & Businesses |
- | - | - | - | - | |
Purchase/Sale of Investments |
- | - | - | - | - | |
Purchase of Investments |
- | - | - | - | - | |
Sale/Maturity of Investments |
- | - | - | - | - | |
Other Uses |
- | - | - | - | - | |
Other Sources |
- | - | - | - | - | |
Net Investing Cash Flow |
- | - | - | - | - | |
Net Investing Cash Flow Growth |
- | - | - | - | - | |
Net Investing Cash Flow / Sales |
- | - | - | - | - | |
Financing Activities
|
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
Cash Dividends Paid - Total |
- | - | - | - | - | |
Common Dividends |
- | - | - | - | - | |
Preferred Dividends |
- | - | - | - | - | |
Change in Capital Stock |
332,495 | 246,449 | (78,611) | 9,217 | 46.74M | |
Repurchase of Common & Preferred Stk. |
- | - | - | - | - | |
Sale of Common & Preferred Stock |
332,495 | 246,449 | (78,611) | 9,217 | 46.74M | |
Proceeds from Stock Options |
332,495 | 246,449 | (78,611) | 9,217 | 46.65M | |
Other Proceeds from Sale of Stock |
- | - | - | - | 95,102 | |
Issuance/Reduction of Debt, Net |
- | - | 521,699 | 12.03M | - | |
Change in Current Debt |
- | - | - | - | - | |
Change in Long-Term Debt |
- | - | 521,699 | 12.03M | - | |
Issuance of Long-Term Debt |
- | - | 521,699 | 12.03M | - | |
Reduction in Long-Term Debt |
- | - | - | - | - | |
Other Funds |
- | - | - | - | - | |
Other Uses |
- | - | - | - | - | |
Other Sources |
- | - | - | - | - | |
Net Financing Cash Flow |
332,495 | 246,449 | 443,088 | 12.04M | 46.74M | |
Net Financing Cash Flow Growth |
- | -25.88% | 79.79% | 2,618.11% | 288.12% | |
Net Financing Cash Flow / Sales |
- | - | - | - | - | |
Exchange Rate Effect |
- | - | - | - | - | |
Miscellaneous Funds |
- | - | - | - | - | |
Net Change in Cash |
(204,986) | (312,160) | (33,454) | 8.07M | 37.61M | |
Free Cash Flow |
(537,480) | (558,610) | (476,540) | (3.97M) | (9.13M) | |
Free Cash Flow Growth |
- | -3.93% | 14.69% | -733.26% | -129.98% | |
Free Cash Flow Yield |
- | - | - | - | -6.81% | NA |